{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:06:00Z","timestamp":1791173160751,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:00:00Z","timestamp":1323388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:00:00Z","timestamp":1323388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s10637-011-9774-6","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T12:53:11Z","timestamp":1323348791000},"page":"2334-2343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies"],"prefix":"10.1007","volume":"30","author":[{"given":"Glen J.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh J.","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Laheru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raoul","family":"Tibes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh K.","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Blaydorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayle","family":"Jameson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Jimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Isaacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Scaburri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Adele","family":"Pacciarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ciomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel D.","family":"Von Hoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"key":"9774_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1042\/CS20050161","volume":"110","author":"SJ Allen","year":"2006","unstructured":"Allen SJ, Dawbarn D (2006) Clinical relevance of the neurotrophins and their receptors. Clinical Science 110:175\u2013191","journal-title":"Clinical Science"},{"key":"9774_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.febslet.2004.06.088","volume":"571","author":"X Montano","year":"2004","unstructured":"Montano X, Djamgoz MB (2004) Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett 571:1\u20138","journal-title":"FEBS Lett"},{"key":"9774_CR3","first-page":"5127","volume":"9","author":"K Ketterer","year":"2003","unstructured":"Ketterer K, Rao S, Friess H, Weiss J, B\u00fcchler MW, Korc M (2003) Reverse transcription-PCR analysis of laser-captured cells points to potential paracrine and autocrine actions of neurotrophins in pancreatic cancer. Clin Cancer Res 9:5127\u20135136","journal-title":"Clin Cancer Res"},{"key":"9774_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1517\/13543784.16.3.303","volume":"16","author":"AG Papatsoris","year":"2007","unstructured":"Papatsoris AG, Liolitsa D, Deliveliotis C (2007) Manipulation of the nerve growth factor network in prostate cancer. Expert Opin Investig Drugs 16:303\u2013309","journal-title":"Expert Opin Investig Drugs"},{"key":"9774_CR5","first-page":"1887","volume":"4","author":"CA Dionne","year":"1998","unstructured":"Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL et al (1998) Cell cycle-independent death of prostate adenocarcinoma is induced by the TRK tyrosine kinase inhibitor CEP-751 (KT6587). Clin Cancer Res 4:1887\u20131898","journal-title":"Clin Cancer Res"},{"key":"9774_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6","volume":"81","author":"SJ Miknyoczki","year":"1999","unstructured":"Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA (1999) Neurotrophins and TRK receptors in human pancreatic Ductal adenocarcinoma: Expression patterns and effects on in vitro invasive behavior. Int J Cancer 81:417\u2013427","journal-title":"Int J Cancer"},{"key":"9774_CR7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1038\/onc.2009.61","volume":"28","author":"C Lagadec","year":"2009","unstructured":"Lagadec C, Meignan S, Adriaenssens E, Foveau B, Vanhecke E, Romon R et al (2009) TRKA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28:1960\u20131970","journal-title":"Oncogene"},{"key":"9774_CR8","first-page":"2248","volume":"9","author":"B Davidson","year":"2003","unstructured":"Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B et al (2003) Expression and activation of the nerve growth factor receptor TRKA in serous ovarian carcinoma. Clin Cancer Res 9:2248\u20132259","journal-title":"Clin Cancer Res"},{"key":"9774_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.canlet.2005.07.043","volume":"232","author":"MA Pierotti","year":"2006","unstructured":"Pierotti MA, Greco A (2006) Oncogenic rearrangements of the NTRK1\/NGF receptor. Cancer Lett 232:90\u201398","journal-title":"Cancer Lett"},{"key":"9774_CR10","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1101\/gad.1256504","volume":"18","author":"CJ Sherr","year":"2004","unstructured":"Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18:2699\u20132711","journal-title":"Genes Dev"},{"key":"9774_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/35106065","volume":"1","author":"M Malumbres","year":"2001","unstructured":"Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1:222\u2013231","journal-title":"Nat Rev Cancer"},{"key":"9774_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/sj.bjc.6602229","volume":"92","author":"C Benson","year":"2005","unstructured":"Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J (2005) Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 92:7\u201312","journal-title":"Br J Cancer"},{"key":"9774_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(03)01321-4","volume":"5","author":"C Swanton","year":"2004","unstructured":"Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27\u201336","journal-title":"Lancet Oncol"},{"key":"9774_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","volume":"183","author":"J Slingerland","year":"2000","unstructured":"Slingerland J, Pagano M (2000) Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10\u201317","journal-title":"J Cell Physiol"},{"key":"9774_CR15","first-page":"203","volume":"48","author":"C Desdouets","year":"2000","unstructured":"Desdouets C, Br\u00e9chot C (2000) p27: a pleiotropic regulator of cellular phenotype and a target for cell cycle dysregulation in cancer. Pathol Biol (Paris) 48:203\u2013210","journal-title":"Pathol Biol (Paris)"},{"key":"9774_CR16","first-page":"M123","volume":"1471","author":"PD Adams","year":"2001","unstructured":"Adams PD (2001) Regulation of the retinoblastoma tumor suppressor protein by cyclin\/cdks. Biochim Biophys Acta 1471:M123\u2013M133","journal-title":"Biochim Biophys Acta"},{"key":"9774_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/ng1232","volume":"35","author":"S Ortega","year":"2003","unstructured":"Ortega S, Prieto I, Odajima J, Mart\u00edn A, Dubus P, Sotillo R et al (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35:25\u201331, Epub 2003 Aug 17","journal-title":"Nat Genet"},{"key":"9774_CR18","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.cub.2003.09.024","volume":"13","author":"C Berthet","year":"2003","unstructured":"Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P (2003) Cdk2 knockout mice are viable. Curr Biol 13:1775\u20131785","journal-title":"Curr Biol"},{"issue":"4","key":"9774_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S0092-8674(03)00649-4","volume":"114","author":"J M\u00e9ndez","year":"2003","unstructured":"M\u00e9ndez J (2003) Cell proliferation without cyclin E-CDK2. Cell 114(4):398\u2013399","journal-title":"Cell"},{"key":"9774_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2004.07.025","volume":"118","author":"K Kozar","year":"2004","unstructured":"Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E et al (2004) Mouse development and cell proliferation in the absence of D-cyclins. Cell 118:477\u2013491","journal-title":"Cell"},{"key":"9774_CR21","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1021\/jm9006559","volume":"52","author":"MG Brasca","year":"2009","unstructured":"Brasca MG, Amboldi N, Ballinari D, Cameron A, Casale E, Cervi G et al (2009) Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem 52:5152\u20135163","journal-title":"J Med Chem."},{"key":"9774_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"9774_CR23","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1177\/0269216308088692","volume":"22","author":"F De Conno","year":"2008","unstructured":"De Conno F, Ripamonti C, Fagnoni E, Brunelli C, Luzzani M, Maltoni M et al (2008) The MERITO Study: a multicentre trial of the analgesic effect and tolerability of normal-release oral morphine during \u2018titration phase\u2019 in patients with cancer pain. Palliat Med 22:214\u2013221","journal-title":"Palliat Med."},{"key":"9774_CR24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.3065","volume":"28","author":"S Cresta","year":"2010","unstructured":"Cresta S, Sessa C, Del Conte G, Locatelli A, Gallerani E, Fiorentini F, et al. Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedule of administration. J Clin Oncol 28:15\u00a0s, 2010 (suppl; abstr 3065)","journal-title":"J Clin Oncol"},{"key":"9774_CR25","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1158\/1535-7163.MCT-10-0190","volume":"9","author":"C Albanese","year":"2010","unstructured":"Albanese C, Alzani R, Amboldi N, Avanzi N, Ballinari D, Brasca MG et al (2010) Dual targeting of CDK and tropomyosin receptor kinase families by the oral inhibitor PHA-848125, an agent with broad-spectrum antitumor efficacy. Mol Cancer Ther 9:2243\u20132254","journal-title":"Mol Cancer Ther"},{"key":"9774_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1023\/B:DRUG.0000047103.64335.b0","volume":"23","author":"JL Marshall","year":"2005","unstructured":"Marshall JL, Kindler H, Deeken J, Bhargava P, Vogelzang NJ, Rizvi N et al (2005) Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Invest New Drugs 23:31\u201337","journal-title":"Invest New Drugs"},{"key":"9774_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/A:1006353008903","volume":"17","author":"AM Senderowicz","year":"1999","unstructured":"Senderowicz AM (1999) Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs 17:313\u2013320","journal-title":"Invest New Drugs"},{"key":"9774_CR28","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","volume":"16","author":"AM Senderowicz","year":"1998","unstructured":"Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L et al (1998) Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986\u20132999","journal-title":"J Clin Oncol"},{"key":"9774_CR29","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-05-0831","volume":"11","author":"JR Brown","year":"2005","unstructured":"Brown JR (2005) Chronic lymphocytic leukemia: a niche for flavopiridol? Clin Cancer Res 11:3971\u20133973","journal-title":"Clin Cancer Res"},{"key":"9774_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","volume":"96","author":"C Benson","year":"2007","unstructured":"Benson C, White J, De Bono J, O\u2019Donnell A, Raynaud F, Cruickshank C et al (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7\u00a0days every 21\u00a0days. Br J Cancer 96:29\u201337, Epub 2006 Dec 19","journal-title":"Br J Cancer"},{"key":"9774_CR31","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/annonc\/mdp377","volume":"21","author":"DS Boss","year":"2010","unstructured":"Boss DS, Schwartz GK, Middleton MR, Amakye DD, Swaisland H, Midgley RS et al (2010) Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol 21:884\u2013894, Epub 2009 Oct 13","journal-title":"Ann Oncol"},{"key":"9774_CR32","doi-asserted-by":"crossref","unstructured":"Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, et al. (2011) Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed\/refractory CLL. J Clin Oncol 29: (suppl; abstr 6623)","DOI":"10.1200\/jco.2011.29.15_suppl.6623"},{"issue":"8","key":"9774_CR33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1080\/10611860903112842","volume":"17","author":"KB Kurakhmaeva","year":"2009","unstructured":"Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS et al (2009) Brain targeting of nerve growth factor using poly (buthyl cyanoacrylate) nanoparticles. J Drug Target 17(8):564\u2013574","journal-title":"J Drug Target"},{"key":"9774_CR34","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-05-0070","volume":"11","author":"A Baldi","year":"2005","unstructured":"Baldi A, Ambrogi V, Mineo D, Mellone P, Campioni M, Citro G et al (2005) Analysis of cell cycle regulator proteins in encapsulated thymomas. Clin Cancer Res 11:5078\u20135083","journal-title":"Clin Cancer Res"},{"key":"9774_CR35","first-page":"2482","volume":"91","author":"F Arguello","year":"1998","unstructured":"Arguello F, Alexander M, Sterry J, Tudor G, Smith EM, Kalavar NT et al (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human and leukemia xenografts. Blood 91:2482\u20132490","journal-title":"Blood"},{"key":"9774_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejcts.2005.06.034","volume":"28","author":"DJ Kim","year":"2005","unstructured":"Kim DJ, Yang WI, Kim SH, Park IK, Chung KY (2005) Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg 28:611\u2013616","journal-title":"Eur J Cardiothorac Surg"},{"key":"9774_CR37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1254\/jphs.10119FP","volume":"114","author":"WY Ma","year":"2010","unstructured":"Ma WY, Murata E, Ueda K, Kuroda Y, Cao MH, Abe M, et al. A synthetic cell-penetrating peptide antagonizing TrkA function suppresses neuropathic pain in mice. J Pharmacol Sci 2010;114:79\u201384. Epub 2010 Aug 11.","journal-title":"J Pharmacol Sci"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9774-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-011-9774-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9774-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-011-9774-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:35:40Z","timestamp":1678559740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-011-9774-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,9]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["9774"],"URL":"https:\/\/doi.org\/10.1007\/s10637-011-9774-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,9]]},"assertion":[{"value":"11 October 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}